Limits...
First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.

Sandercock J, Parmar MK, Torri V, Qian W - Br. J. Cancer (2002)

Bottom Line: Four main explanations for this heterogeneity have been proposed: differences in the extent and timing of 'crossover' to taxanes in the control groups; differences in the types of patient included; differences in the effectiveness of the research regimens used; differences in the effectiveness of the control regimens used.Heterogeneity 'within' and 'between' groups was formally compared using the F-ratio.Further investigation of this question would be useful.

View Article: PubMed Central - PubMed

Affiliation: Department of Public Health and Epidemiology, University of Birmingham, Birmingham, UK.

Show MeSH

Related in: MedlinePlus

Randomised trials comparing platinum as a single agent with platinum in combination (Adapted from AOCTG, 1998).
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2376171&req=5

fig3: Randomised trials comparing platinum as a single agent with platinum in combination (Adapted from AOCTG, 1998).

Mentions: The pooled results of all of these trials suggested a benefit to combination regimens (AOCTG, 1998). However, it is useful to examine that analysis in more detail, separating the trials into those which used platinum at the same dose in both the single agent and combination arms and those that increased the dose in the single agent arm. A summary of these trials split in this way is given in Table 5Table 5Trials comparing single agent platinum vs platinum in combination and the meta-anaylsis plots are given in Figure 3Figure 3


First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence.

Sandercock J, Parmar MK, Torri V, Qian W - Br. J. Cancer (2002)

Randomised trials comparing platinum as a single agent with platinum in combination (Adapted from AOCTG, 1998).
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2376171&req=5

fig3: Randomised trials comparing platinum as a single agent with platinum in combination (Adapted from AOCTG, 1998).
Mentions: The pooled results of all of these trials suggested a benefit to combination regimens (AOCTG, 1998). However, it is useful to examine that analysis in more detail, separating the trials into those which used platinum at the same dose in both the single agent and combination arms and those that increased the dose in the single agent arm. A summary of these trials split in this way is given in Table 5Table 5Trials comparing single agent platinum vs platinum in combination and the meta-anaylsis plots are given in Figure 3Figure 3

Bottom Line: Four main explanations for this heterogeneity have been proposed: differences in the extent and timing of 'crossover' to taxanes in the control groups; differences in the types of patient included; differences in the effectiveness of the research regimens used; differences in the effectiveness of the control regimens used.Heterogeneity 'within' and 'between' groups was formally compared using the F-ratio.Further investigation of this question would be useful.

View Article: PubMed Central - PubMed

Affiliation: Department of Public Health and Epidemiology, University of Birmingham, Birmingham, UK.

Show MeSH
Related in: MedlinePlus